ODC1 is also one of the transcriptional targets of MYCN, and thus high expression of ODC1 is found in MYCN-amplified neuroblastoma, linking this marker to poor outcomes in children.309 Another interesting consideration is the recent development of difluoromethylornithine (DFMO) which has been developed for inhibition of ODC1.312 Thus, a tool for the detection of ODC1 could be used not only for diagnosis, but also for monitoring of treatment efficacy. This evidence concerns the gene MYCN and neuroblastoma.